Inflammatory Breast Cancer

Inflammatory breast cancer (IBC) is a rare and aggressive form of breast cancer. In this post, I will discuss our most recent understanding of this aggressive disease.

almost all women with IBC have lymph node involvement at the time of diagnosis.

Continue reading “Inflammatory Breast Cancer”

Endocrine Therapy for Early Breast Cancer

In this blog post, I will review the current recommendation of endocrine therapy for early non-metastatic breast cancer hormone positive breast cancer (Estrogen receptor positive ER + and/or Progesterone receptor positive PR +), this is most often referred to as Adjuvant hormonal or Adjuvant Endocrine therapy, for discussion regarding the use of endocrine therapy for metastatic breast cancer please refer to my earlier post by clicking here.

Hormone receptor-positive Breast cancer comprise 75% of all cases.

Endocrine therapy is of significant benefit and Generally well tolerated.

Continue reading “Endocrine Therapy for Early Breast Cancer”

Adjuvant Capecitabine the CREAT-X trial

CREAT-X, Capcetabine for Residual Cancer as Adjuvant Therapy trial is the first of it’s kind to look into further adjuvant chemotherapy in patients who received neoadjuvant chemotherapy.

Capecitabine adjuvant therapy is beneficial in Her2-negative Breast cancer with residual disease following Neoadjuvant therapy.

 

Continue reading “Adjuvant Capecitabine the CREAT-X trial”

Extended Therapy with Neratinib for HER2 Positive Breast Cancer

Neratinib is now approved for use in HER2 positive patients who completed their Trastuzumab-based therapy. This came following the publication of a phase 3 trial with the result indicating the benefit of Neratinib as compared to placebo. In the following blog post I will discuss the result of the ExteNET trial.

Continue reading “Extended Therapy with Neratinib for HER2 Positive Breast Cancer”